Open Access Journal of Clinical Trials is a premier peer-reviewed journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of clinical pharmacology and medical research. With an impactful open access model initiated in 2009, this journal makes valuable research widely accessible, fulfilling the urgent need for rapid dissemination of scientific knowledge. The journal has established itself as a significant resource in its field, boasting impressive metrics with a 2023 Q2 ranking in Pharmacology (Medical) and a Q1 ranking in the Miscellaneous subsector of Pharmacology, Toxicology, and Pharmaceutics, underscoring its reputation for excellence. Based in New Zealand, the journal fosters global collaboration, and its comprehensive coverage spans various domains within pharmacology and clinical trials. Researchers and practitioners are encouraged to contribute to this vital discourse, as the journal serves as a platform for innovation, collaboration, and the exchange of groundbreaking findings in clinical trials.

American Journal of Hypertension, published by Oxford University Press, is a leading peer-reviewed journal dedicated to the field of hypertension and cardiovascular health. With an ISSN of 0895-7061 and an E-ISSN of 1941-7225, this prestigious journal has been providing researchers and clinicians with significant advancements in hypertension research since its inception in 1954, with a continued focus on innovative studies through 2024. Ranked Q2 in Internal Medicine and positioned within the top 22% of its category according to Scopus, it is a vital resource for those involved in clinical practice and research aimed at understanding and managing hypertension. The journal disseminates pivotal findings, treatment updates, and guideline recommendations that contribute to improved patient care globally. Accessible solely through subscription, the American Journal of Hypertension is essential reading for professionals committed to enhancing cardiovascular health outcomes.

Journal of Clinical Medicine Research-Canada is a prestigious and dynamic platform dedicated to the dissemination of novel research in the field of medicine. Published by ELMER PRESS INC, the journal has gained a significant reputation since its inception, achieving an impressive Q2 ranking in the Medicine (miscellaneous) category and placing within the 85th percentile of general medicine rankings in Scopus. This indicates its notable contribution and relevance within the medical community. As an active participant in global healthcare discussions, the journal covers a wide spectrum of topics, ranging from clinical practices to innovative therapeutic interventions. With its commitment to delivering high-quality, peer-reviewed content, the Journal of Clinical Medicine Research-Canada serves as an invaluable resource for researchers, professionals, and students looking to stay at the forefront of medical advancements. Though currently not an Open Access journal, it remains a critical publication for those seeking to deepen their understanding and engage with cutting-edge research in the field. The journal is headquartered in Ontario, Canada, and encourages submissions that push the boundaries of clinical medicine, thereby fostering an environment of scholarly excellence.

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

Pilot and Feasibility Studies, published by BMC, stands at the forefront of innovative research in the realm of pilot studies and feasibility assessments, serving as a vital resource for researchers in medicine and healthcare. As an Open Access journal since 2015, it provides unrestricted access to its content, promoting the dissemination of significant findings and fostering collaboration among the global research community. Based in the United Kingdom, this journal has solidly established its reputation, ranking in the Q2 quartile for medicine (miscellaneous) in 2023 with a Scopus rank of #183 out of 398, placing it within the 54th percentile. The journal's scope encompasses a wide range of methodologies and applications, encouraging the translation of pilot studies into viable healthcare practices. With a commitment to quality and accessibility, Pilot and Feasibility Studies plays an essential role in enhancing the rigor and impact of preliminary research, ultimately contributing to the advancement of medical science.

Diabetes Therapy is a prominent open access journal published by SPRINGER HEIDELBERG, dedicated to advancing our understanding of diabetes management and therapeutic strategies. Since its inception in 2010, the journal has provided a platform for high-quality research, showcasing innovative studies and clinical advances aimed at improving care for individuals with diabetes. With an established impact factor and categorized within the Q2 quartile in both Endocrinology, Diabetes and Metabolism and Internal Medicine in 2023, it ranks among the top journals in its field, reflecting its significant contribution to medical knowledge. Researchers, healthcare professionals, and students benefit from its comprehensive coverage of critical topics, ranging from pharmacological advancements to lifestyle interventions and cutting-edge technologies in diabetes management. With a Scopus rank placing it 35th in Internal Medicine, and 68th in Endocrinology, Diabetes, and Metabolism, Diabetes Therapy is recognized for its robust peer-reviewed content, making it an essential resource for anyone engaged in diabetes research and care.

The New England Journal of Medicine (NEJM), published by the Massachusetts Medical Society, stands as a beacon of excellence in the field of medicine. With an impressive impact factor and a prestigious rank of #2 out of 636 in General Medicine, NEJM is recognized in the Q1 category for its significant contributions to medical research and clinical practice since its inception in 1945. The journal is renowned for publishing groundbreaking studies, reviews, and commentaries that influence clinical guidelines and healthcare policies worldwide. While the journal is not open access, it provides pivotal resources that are essential for researchers, healthcare professionals, and students looking to stay abreast of the latest developments in medicine. With a commitment to advancing medical knowledge, NEJM plays a crucial role in bridging the gap between laboratory research and clinical application.

Therapeutic Innovation & Regulatory Science, published by Springer Heidelberg, is an esteemed journal that focuses on the intersection of therapeutic innovations and the regulatory frameworks that govern them. Established in 1970 and continuing its legacy of excellence through converged years, this journal plays a crucial role in supplying cutting-edge research, reviews, and discussions that advance understanding in the fields of pharmacology and healthcare regulation. With an impact factor reflective of its rigorous peer-review standards, this journal holds a prestigious Q1 ranking in Pharmacology, Toxicology, and Pharmaceutics (Miscellaneous) for 2023, reflecting its influence and the high quality of its published material. The journal's wide scope also embraces public health and environmental studies, making it an essential resource for researchers and professionals navigating these critical areas. Open access options enhance its visibility and accessibility, ensuring that the latest discoveries and regulatory insights are readily available to a global audience. For those at the forefront of medicinal science and regulatory affairs, Therapeutic Innovation & Regulatory Science is your avenue to understanding pivotal innovations that shape contemporary therapeutic practices.

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

HEALTH TECHNOLOGY ASSESSMENT is a prestigious open-access journal published by the NIHR Journals Library, focusing on advancing the science of health technology assessment through robust research and critical analysis in the fields of Health Policy and Medicine. Since its inception in 2001, this journal has fostered a multidisciplinary approach to evaluating health technologies, offering invaluable insights to researchers, healthcare professionals, and policymakers. With an impressive Q1 ranking in both Health Policy and Medicine (miscellaneous) for 2023, it stands at the forefront of academic discourse, reflecting a high-impact factor and an esteemed reputation within its respective categories. The journal not only publishes original research articles, but also reviews and case studies that illuminate the complexities of health technology in real-world applications. Established and based in the United Kingdom, HEALTH TECHNOLOGY ASSESSMENT strives to encourage evidence-based decision-making, making it an essential resource for anyone committed to enhancing healthcare outcomes through innovative technology assessments.